Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Active:	Yes
Cancer Type:	Solid Tumor	NCT ID:	NCT03391778
Trial Phases:	Phase I	Protocol IDs:	208750 (primary) NCI-2018-01288 ADP-0000-002
Eligibility:	0 Years and older, Male and Female	Study Type:	Other
Study Sponsor:	Adaptimmune Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT03391778

Summary

This trial will evaluate long term safety of participants who have received AdaptImmune
(ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy
infusion.

Objectives

Participants who received a ADP adoptive cell therapy will be enrolled in this
non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for
up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy.
Participants will be monitored for safety following last adoptive cell therapy infusion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.